-

Shareholder Rights Law Firm Robbins LLP Urges Agilon Health, Inc. Stockholders to Seek Information About Their Rights Against AGL

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired agilon health, inc. (NYSE: AGL) securities between February 26, 2025 and August 4, 2025. Agilon describes itself as the "trusted partner empowering physicians to transform health care in our communities."

Robbins LLP is Investigating Allegations that Agilon Health, Inc. (AGL) Misled Investors Regarding its Business Prospects

Share

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What are the allegations? Robbins LLP is Investigating Allegations that Agilon Health, Inc. (AGL) Misled Investors Regarding its Business Prospects

According to the complaint, defendants failed to disclose that they recklessly issued guidance for 2025 that they knew or should have known was not going to be achieved, given material industry headwinds of which they were aware, and materially overstated the immediate positive financial impact from “strategic actions” taken by agilon to reduce risk.

On August 4, 2025, agilon issued a press release announcing that Steven Sell had stepped down as President, CEO and a Director of the Board. Plaintiff alleges that the Company's form 8-K filed with the SEC stated that "Mr. Sell's departure was a termination without 'cause' under Mr. Sell's employment agreement[.]" The complaint further alleges that on August 4, 2025, agilon issued disappointing financial results. On this news, the price of the Company's stock fell over 50%, to close at $0.8801 on August 5, 2025.

What can you do now? You may be eligible to participate in the class action against agilon health, inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by March 2, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against agilon health, inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:AGL

Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the SES AI Corporation Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired SES AI Corporation (NYSE: SES) securities between January 29, 2025 and March 4, 2026. SES claims to be a "leading developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (“Li-Metal”) and Lithium-ion (“Li-ion”) rechargeable battery technologies and battery materials for Energy Storage Systems (“ESS”), Urban Air Mobility (“UAM”)...

Investor Notice: Robbins LLP Informs Investors of the Regencell Bioscience Holdings Limited Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

Investor Notice: Robbins LLP Informs Investors of the Globant S.A. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Globant S.A. (NYSE: GLOB) common stock between February 15, 2024 and August 14, 2025. Globant is a Luxembourg-incorporated international technology company that provides digital consulting and related services. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LL...
Back to Newsroom